---
schema_version: "secwatch.filing_event.v1"
accession: "0001641172-25-009580"
form_type: "8-K"
ticker: "AIMD"
cik: "0001014763"
company_name: "Ainos, Inc."
filed_at: "2025-05-12T23:59:59+00:00"
generated_at: "2026-05-21T22:41:26.322259+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Ainos Q1 revenue up 412% to $106K; gross profit swings to positive; partnerships in robotics and semiconductors

## Summary
- Revenue up 412% YoY to $106,207; gross profit of $87,974 vs prior-year gross loss of $6,025.
- Cost of revenue down 32% YoY to $18,233, driving gross margin improvement.
- AI Nose deployed in semiconductor manufacturing via ASE partnership; olfactory module installed on ugo robots.
- VELDONA secured TFDA approval for HIV oral warts trial and IRB clearance for Sjögren's syndrome trial.
- No net income or EPS disclosed; share-based compensation increased SG&A expenses.

## SEC filing metadata
- accession: 0001641172-25-009580
- form_type: 8-K
- ticker: AIMD
- cik: 0001014763
- company_name: Ainos, Inc.
- filed_at: 2025-05-12T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1014763/000164117225009580/0001641172-25-009580-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1014763/000164117225009580/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001641172-25-009580
- JSON: https://secwatch.observer/filing/0001641172-25-009580.json
- Plain text: https://secwatch.observer/filing/0001641172-25-009580.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.